Echocardiography represents the first-line cardiovascular imaging (CVI) modality for the assessment of patients with HF.
Cardiac magnetic resonance (CMR), single photon emission computed tomography (SPECT), positron emission tomography (PET), and cardiac computed tomography (CCT) complement echocardiography or represent an alternative to it in the case of suboptimal acoustic window.
The same CVI modality should be used at follow-up to ensure comparability.
A baseline echocardiogram is performed before commencing treatment to assess LV systolic and diastolic function, the valves and unexpected abnormalities.
Screening first-degree relatives of cardiomyopathy patients, we can identify individuals with cardiomyopathy and subclinical or clinical HF.
HF is defined as a syndrome consisting of symptoms and signs resulting from an abnormality of cardiac structure and/or function.The screening timing and follow-up intervals have been described by the ESC Working Group on Myocardial and Pericardial Diseases.Patients on cardiotoxic chemotherapy often undergo periodic LV systolic function screening, despite lack of HF symptoms or signs.The demand for CVI in HF is constantly increasing as a result of continuously evolving technology, diversification of indications, and rise in HF prevalence, partially due to better life expectancy and higher HF prevalence in the elderly.The increasing demand necessitates appropriateness criteria for CVI use in HF to assist decision-making.